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SUMMARY
Publications are often used as a measure of research work success. Human T-lymphotropic virus (HTLV) type 1 and 2 are human 
retroviruses, which were discovered in the early 1980s, and it is estimated that 15-20 million people are infected worldwide. This article 
describes a bibliometric review and a coauthorship network analysis of literature on HTLV indexed in PubMed in a 24-year period. A 
total of 7,564 documents were retrieved, showing a decrease in the number of documents from 1996 to 2007. HTLV manuscripts were 
published in 1,074 journals. Japan and USA were the countries with the highest contribution in this field (61%) followed by France 
(8%). Production ranking changed when the number of publications was normalized by population (Dominican Republic and Japan), 
by gross domestic product (Guinea-Bissau and Gambia), and by gross national income per capita (Brazil and Japan). The present 
study has shed light on some of the defining features of scientific collaboration performed by HTLV research community, such as 
the existence of core researchers responsible for articulating the development of research in the area, facilitating wider collaborative 
relationships and the integration of new authors in the research groups.
KEYWORDS: Human T-lymphotropic virus (HTLV); T cell leukemia/lymphoma; Tropical spastic paraparesis; Bibliometrics; 
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INTRODUCTION
Four different types of human T-lymphotropic viruses (HTLV) have 
been described in humans. Human T-lymphotropic virus type 1 (HTLV-1) 
was the first retrovirus infecting humans to be discovered in 19801, and 
15-20 million people are estimated to be infected worldwide2-4. Endemic 
foci of infection have been reported in Japan, Melanesia, Iran, Central 
and West Africa, the Caribbean, and South America5. In Europe, North 
America, and Australia, HTLV-1 infection is rare and mainly found 
in immigrants coming from endemic areas, and their sexual partners 
and descendants6,7. Although most HTLV-1-infected people remain 
asymptomatic throughout their lives, approximately 3% develop adult 
T cell leukemia/lymphoma (ATLL) and another 3% develop HTLV-1-
associated myelopathy/tropical spastic paraparesis (HAM/TSP)8. 
HTLV-2 was discovered in 1982, and it is estimated that 3-5 million 
people are chronically infected. It is mostly prevalent among intravenous 
drug users in North America and Western Europe, although endemic 
infections can be found in some Amerindian and African pygmy tribes. In 
contrast to HTLV-1, the pathogenicity of HTLV-2 is very low and has only 
occasionally been linked to subacute neurological syndromes, including 
HTLV-2-like paraparesis, neuropathies, and bladder disturbances7,9-14. 
In 2005, HTLV type 3 (HTLV-3) was discovered in two asymptomatic 
inhabitants from South Cameroon. More recently, two other cases of 
HTLV-3 infection in people living in Cameroon were reported, suggesting 
that this virus is not extremely rare in the human population living in 
Central Africa15. Finally, only one strain of HTLV-4 has been identified 
in a person who also lived in Cameroon16. 
The basic premise for bibliometrics is that scientific knowledge is 
mainly transmitted through publications that report research results, 
which in turn allowed us to analyze the development of the scientific 
field in question. By carrying out a quantitative analysis of scientific 
publications in a given field, we can draw conclusions on how that 
research field evolves and develops17,18. 
There have been publications analyzing research production for 
other viral infections, such as John Cunningham virus19, Nipah virus20, 
avian influenza virus21, H1N1 influenza virus22, and papillomavirus23 
among others. As for HTLV, one short quantitative study analyzing 
research output for the period between 2001 and 2010 using the PubMed 
was reported at an international conference as a poster presentation24. 
Another study analyzed scientific production in the field of the motor 
neuron diseases, Konzo and neurolathyrism, in comparison with HTLV-
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1/ HAM/TSP over 21 years (from 1990 to 2010) through the Web of 
Science database25. As HTLV-1 can be considered a neglected public 
health problem26, and ATLL and HAM/TSP can be considered neglected 
diseases, this would provide more focus on this condition27. 
The aim of this study was to investigate HTLV research output 
using PubMed database, covering a period of 24 years (1989-2012): by 
journal of publication, country, forms of disease, author production, and 
collaboration patterns. 
METHODS
The Medline database, accessible and free of charge through the 
PubMed platform, was selected as the most suitable database to search 
for HTLV publications, due to its volume and coverage. PubMed was 
accessed online in December 28, 2013. For retrieving documents, a 
search was made comprising the MeSH terms or descriptors: “Human 
T-lymphotropic virus 1”, “Human T-lymphotropic virus 2”, “Human 
T-lymphotropic virus 3”, “HTLV-II Antigens”, “HTLV-II Antibodies”, 
“HTLV-I Antigens”, “HTLV-I Antibodies”, “HTLV-II Infections”, and 
“HTLV-I Infections”. The study period was from January 1, 1989 to 
December 31, 2012. We decided to begin in 1989 because a different 
HTLV MeSH term was introduced in 1989. No language or document 
type restriction was considered in the search, so that publication patterns 
for all publications on HTLV could be analyzed.
The document type used in our study refers to the type of article 
according to PubMed (journal article, letter, editorial, review, etc.). 
Financial support was analyzed. 
Productivity by country was analyzed considering the number of 
papers and percentage of world production. It should be noted that 
institutional affiliation is only included for the first participating author 
in the PubMed database in Journal articles and Reviews. Indicators for 
each country’s productivity between 1989 and 2012 were standardized 
with respect to the median population, gross domestic product (GDP), 
GDP per capita and health expenditure (HE) per capita. To calculate the 
publications per million inhabitants (population index), per 10 billion 
US dollars of GDP (GDP index), per 1,000 US dollars of GDP per capita 
(GDP per capita index), and per 100 US dollars of HE per capita (HE per 
capita index), data were obtained from World Development Indicators 
from the World Bank online databases28. 
Based on geographical, scientific, and economic criteria, the 
world was divided into six regions according to the composition of 
macrogeographical (continental) regions, geographical subregions, and 
selected economic regions and other unidata groupings from the United 
Nations Statistics Division29. The forms of diseases were classified as 
HTLV-I, HTLV-II, ATLL and HAM/TSP according to the MeSH term. 
A number of widely used bibliometric indicators were calculated 
to characterize the scientific collaboration on HTLV, the percentage 
of documents signed in collaboration and the average number of 
coauthors per paper. A coauthorship network analysis was carried out. 
Coauthorship networks are made up of nodes (authors) and ties between 
them (coauthorship links). We identified the nodes that function as 
“cutpoints” or intermediates facilitating connectivity between parts of 
the network that would otherwise be unconnected, and we also made 
different statistical calculations relating to centrality. These indicators 
are commonly used in Social Network Analysis (SNA) and include the 
concept of “degree” and “betweenness,” used to characterize the role 
played by different investigators in the network and to determine the 
most important and influential authors in it. BibExcel software was used 
for the treatment and standardization of the bibliographical information, 
and the Pajek program was used to analyze and generate a visualization 
of the coauthorship network.
The Committee for Security of Information and Research at the 
Hospital General Universitario de Alicante provided ethical approval 
for this study.
 
RESULTS
In the PubMed database, a total of 7,564 references were retrieved 
during the entire study period. The number of documents decreased 
during the overall study period; the global figures per six-year period are 
as follows: 2,717 (35.9%) publications from 1989 to 1994; 2,236 (29.6%) 
from 1995 to 2000; 1,387 (18.3%) from 2001 to 2006; and 1,224 from 
2007 to 2012 (16.2%) (Fig. 1). 
Language and type of documents: The primary language was 
English (89.1%), followed by Japanese (5.1%), Spanish (2.0%), and 
French (1.7%). The main type of document was “Original paper 
contribution” (77.8%), followed by “Review” (11.7%), and “Letter” 
(8.5%). Almost 53% of documents were original researches, only 0.8% 
were clinical trials, and 0.04% were meta-analysis studies.
Journal of publication: The 7,564 retrieved articles were published 
in 1,074 different scientific journals. Ten journals accounted for 25.8% of 
HTLV journal literature. About one half of the articles was concentrated 
in 44 journals, while the remaining half was spread over 1,030 journals. 
Moreover, 498 journals published only one paper on HTLV. The journals 
area mainly include the fields of virology (n = 10), hematology (n = 9), 
immunology (n = 8), oncology (n = 7), clinical neurology (n = 5), and 
infectious diseases (n = 5) among others.
Topics and MeSH: The MeSH “Human T-lymphotropic virus 1”, 
“HTLV infection”, “HTLV-I Antibodies”, “HTLV-II Infections”, “Human 
T-lymphotropic virus 2”, “HTLV-II Antibodies”, “HTLV-I Antigens”, 
and “HTLV-II Antigens” were reported in 62.8%, 40.7%, 14.8%, 10.4%, 
Fig. 1 - Number of HTLV research publications in PubMed between 1989 and 2012, per 
6-year period.
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10.1%, 3.8%, 2.6%, and 0.4% of articles respectively. About 88.5% of 
documents (n = 6,697) were about HTLV-I, 16.6% of documents (n = 
1,259) were about HTLV-II, and 12.3% of documents referred to both 
HTLV-I and HTLV-II. 
The main MeSH infections associated with HTLV were: “Paraparesis, 
Tropical Spastic” (18.8%), “Leukemia-Lymphoma, Adult T-Cell” 
(11.9%), “Leukemia, T-Cell” (4.8%), “Skin Neoplasms” (1.4%), 
and “Uveitis” (1.2%). The main MeSH associated with virology of 
HTLV were: “Molecular Sequence Data” (15.9%), “Gene Products, 
tax” (13.8%), “DNA viral” (12.2%), “Cell Line” (12.1%), and “Base 
sequence” (11.9%). The MeSH “HIV 1”, “HIV Infections”, “HIV-2”, 
“HIV”, “HIV antibodies”, and “HIV seropositivity” were reported in 
7.5%, 5.8%, 1.8%, 1.8%, 1.7%, and 1.5% of documents. 
Countries of publication: Authors’ affiliation was available in 6,590 
of the 7,564 documents recovered (87.1%). Table 1 ranks countries in 
crude numbers of retrieved articles and numbers corrected by population 
index, GDP index, GNI per capita index, and HE per capita index. The 
first and second countries were Japan and USA, respectively, accounting 
for more than 61% of publications, followed by France, Brazil, and United 
Kingdom. When normalized by population, the order of prominence was 
Dominica, Japan, Jamaica, Curacao, and Grenada. Once normalized 
by GDP, we found that among low and middle-income countries, 
Guinea-Bissau, Gambia, Dominica, Jamaica, and Saint Vincent and the 
Grenadines were the most productive. If we calculate the ratio of the 
number of HTLV publications to GDP per capita, Brazil, Japan, USA, 
China, and India were the most productive. When normalized by HE per 
capita, the leading order was Brazil, Japan, India, China, and Democratic 
Republic of the Congo.
Asia and North America were by far the most productive continents 
in the field of HTLV, responsible for 64.4% of all articles (Table 1). The 
ranking corrected by population ranked North America and Europe in 
first position, and when normalized by GDP, the order of prominence 
was Latin America and the Caribbean, followed by North America. Once 
normalized by GDP per capita, the leading order was North America 
and Asia, and after being normalized by HE per capita, Asia and North 
America were the most productive (Table 1). 
Japan and USA were the most productive countries regarding HTLV-
1. USA ranked first in HTLV-II followed by Brazil. Japan followed by 
USA and Brazil were the most productive in HAM/TSP. In ATLL, Japan 
followed by USA and France were in the lead. Asia, North America, and 
Europe ranked first in HTLV-I and ATLL; North America, Europe, Latin 
America and the Caribbean led in HTLV-II; and Asia, North America, and 
Latin America and the Caribbean had the highest number of publications 
in HAM/TSP (Table 2). 
Authorship: Table 3 ranks the 20 most productive authors for each 
form of the disease. For global HTLV research, the main author was 
M. Osame, a Japanese researcher (n = 217 documents), followed by 
A. Gessain (n = 158), a French investigator, and Y. Tanaka (n = 150), 
another Japanese scientist. For HTLV-1, the main author was M. Osame 
(n = 146), Y. Tanaka (n = 142) and A. Gessain (n = 141). In HTLV-2, 
the main author was R.B. Lal (n = 64), a North American researcher, 
followed by E.L. Murphy (n = 58), another North American investigator 
and V. Soriano (n = 48), a Spanish scientist. M. Osame (n = 170) led in 
HAM/TSP research, while M. Matsuoka (n = 48) led in ATLL research. 
Collaboration networks: Nearly all of the “original paper 
contributions” (96.66%, n = 5,671) were signed in collaboration, at an 
average number of 6.2±3.0 coauthors per paper. The evolution through 
time shows a steady increase in collaborative work, rising from an average 
of 5.6 ± 2.8 authors per work in 1989 to 7.2 ± 4.0 in 2012. 
Virtually all of the authors (99.7%) established at least one 
collaborative link; on average, they collaborated with 11.7 other authors 
on different papers. Among the most productive authors (> 9 papers), 
this number was considerably higher, at 71.6 ± 56.6. However, these 
authors only had consolidated, stable ties with a handful of colleagues; 
the average number of collaborators with whom they had signed eight 
or more papers was 2.4±3.0.
Quantifying the different author pairs, we identified 88,919 
coauthorship links. Most of these collaborations were isolated, as 83.3% 
(n = 74,063) were limited to coauthoring one paper, whereas 9.8% (n 
= 8,763) of the pairs coincided twice and 6.3% (n = 5,673) of the ties 
were present in 3-9 papers.
Only 420 (0.5%) of the coauthorships occurred in 10 or more 
documents. An analysis and graphical representation of all the 
coauthorship links in the form of a network show that 85.1% (n = 
12,952) of the authors appear interconnected, either directly or through 
intermediates in a larger research group or in a main component. 
We applied a collaboration threshold of eight or more coauthored 
articles in order to identify and analyze the main research groups, with 
the most consolidated relationships among its members. We were able 
to identify 80 clusters, made up of 516 authors. One large group stands 
out, bringing together 174 authors and six other clusters, each of which 
consists of more than nine authors. The authors that participate in these 
clusters are specialized in the study of the same disease in the same 
geographical proximity; they come primarily from Japan, the USA, 
and a few European countries, including Belgium, France, and Spain. 
Calculating the centrality measures used in SNA and identifying the 
cutpoints it was possible to show how some authors exercise a prominent 
role as intermediates, bringing together a high number of investigators, 
or facilitating links between dispersed authors and research foci in the 
network. Y. Tanaka heads the ranking by betweenness (indicator of 
the node’s centrality in the network), followed by C.R.M. Bangham, 
S. Kamihira, K. Yamaguchi, and Y. Yamada. M. Osame is the first in 
degree (number of ties that a vertex has to other vertices in its network), 
followed by S. Izumo, T. Nakamura, A. Gessain, V. Soriano, Y. Tanaka, 
and E.L. Murphy. Table 4 lists the top 17 authors ranking according 
betweenness and degree of centrality measures as well as the number of 
published original articles, and Fig. 2 is a graphical visualization of the 
main research foci, with labels to identify the most prominent authors.
DISCUSSION
Some authors have highlighted the importance of HTLV-1-associated 
myelopathy/tropical spastic paraparesis, the main disease associated 
with HTLV-1, that many consider to be neglected27. Its burden is 
overwhelmingly concentrated (with the exception of Japan) in poor 
countries; there is no adequate intervention for its prevention or treatment, 
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and neither the pharmaceutical industry nor other private funders have 
invested much in research on the topic26. Moreover, few studies offer 
current data on the disease’s prevalence or incidence in countries where 
it is endemic or on the high proportion of underdiagnosed cases and 
late diagnosis a consequence of its asymptomatic nature. There is also 
a dearth of studies investigating treatments for the diseases associated 
with the virus3. The formal consideration of tropical spastic paraparesis 
(and by extension, HTLV) as a neglected disease would be in the interest 
of researchers on the topic, providing as the classification has for other 
neglected diseases an impulse for new studies. The most prominent, 
current authors and research groups on HTLV could then become 
reference points, facilitating the integration of new investigators.
Table 1
Top 20 countries and world regions ranked according to total number of publications, publications per inhabitant, per gross domestic product (GDP), GDP per capita 
and health expenditure (HE) per capita in 6,590 human T-lymphotrophic virus manuscripts with institutional address of the first author. 
Country N. of docs. (%) Country
Population 
index* Country
GDP 
index** Country
GDP per 
capita 
index***
Country
HE per 
capita 
index****
1.Japan 2,116 (32.1) 1.Dominica 28.27 1.Guinea-Bissau 175.81 1.Brazil 78.57 1.Brazil 90.28
2.USA 1,952 (29.6) 2.Japan 16.74 2.Gambia 82.63 2.Japan 59.58 2.Japan 74.25
3.France 524 (8.0) 3.Jamaica 14.78 3.Dominica 63.39 3.USA 52.83 3.India 57.65
4.Brazil 415 (6.3) 4.Curaçao 14.44 4.Jamaica 42.39 4.China 26.09 4.China 48.99
5.UK 248 (3.8) 5.Grenada 9.86 5.St.Vincent ## 41.75 5.India 25.46 5.Congo### 43.84
6.Italy 194 (2.9) 6.St.Vincent## 9.23 6.Grenada 23.11 6.Guinea-Bissau 24.15 6.Guinea-Bissau 34.14
7.Germany 106 (1.6) 7.Gabon 8.78 7.Gabon 20.06 7.Congo### 23.01 7.Mozambique 33.97
8.Canada 85 (1.3) 8.France 8.51 8.Lebanon 13.76 8.Mozambique 22.03 8.USA 32.58
9.Spain 77 (1.2) 9.Israel 7.46 9.Mozambique 13.60 9.France 18.03 9.South Korea 28.14
10.Belgium 60 (0.9) 10.Lebanon 7.45 10.Central A. R.#### 10.89 10.Nigeria 14.22 10.Gambia 27.80
11.Chile 54 (0.8) 11.USA 6.92 11.Senegal 7.33 11.Peru 13.72 11.Peru 26.20
12.Israel 47 (0.7) 12.Guinea-Bissau 6.15 12.South Korea 6.54 12.Jamaica 11.06 12.Ethiopia 24.58
13.China 45 (0.7) 13.Belgium 5.78 13.Trinidad# 6.28 13.Gambia 10.45 13.Jamaica 19.90
14.Australia 42 (0.6) 14.Denmark 5.61 14.Peru 5.13 14.Ethiopia 9.88 14.Tanzania 17.95
15.Argentina 41 (0.6) 15.Trinidad# 4.70 15.Togo 5.06 15.Iran 9.38 15.Nigeria 17.80
16.Peru 39 (0.6) 16.Gambia 4.67 16.Chile 5.05 16.Tanzania 9.32 16.France 15.36
17.Jamaica 38 (0.6) 17.UK 4.17 17.Congo### 5.04 17.UK 8.62 17.Cameroon 14.25
18.Sweden 33 (0.5) 18.Ireland 3.80 18.Japan 4.71 18.Chile 8.12 18.Ghana 14.11
19.Netherlands 31 (0.5) 19.Barbados 3.71 19.Brazil 4.33 19.Ghana 7.80 19.Bangladesh 13.97
20.Denmark 30 (0.5) 20.Sweden 3.69 20.Cameroon 4.11 20.Italy 7.59 20.Senegal 12.76
World region N. of docs. World region Population index* World region
GDP in-
dex** World region
GNI per 
capita 
index***
World region
HE per 
capita 
index****
1.Asia 2,223 (33.7) 1.North America 6.50 1.Latin America & 
the Caribbean
2.43 1.North America 30.68 1.Asia 31.69
2.North America 2,037 (30.9) 2.Europe 1.95 2.North America 1.76 2.Asia 12.43 2.North America 22.33
3.Europe 1,419 (21.5) 3.Oceania 1.73 3.Sub-Saharan Africa 1.69 3.Latin America 
& the Caribbean
2.29 3.Latin America 
& the Caribbean
6.00
4.Latin America & 
the Caribbean
658 (10.0) 4.Latin America 
& the Caribbean
1.23 4.Asia 1.17 4.Europe 1.44 4.Sub-Saharan 
Africa
2.53
5.North Africa 125 (1.9) 5.Asia 0.66 5.Europe 1.10 5.Sub-Saharan 
Africa
1.38 5.Europe 1.99
6.Sub-Saharan 
Africa
86 (1.3) 6.North Africa 0.30 6.North Africa 0.73 6.North Africa 0.64 6.North Africa 1.46
7.Oceania 42 (0.6) 7.Sub-Saharan 
Africa
0.14 7.Oceania 0.61 7.Oceania 0.53 7.Oceania 0.70
Total 6,590 (100) Total 1.08 Total 1.66 Total 3.22 Total 5.21
N.: number; Docs.: documents; # Trinidad: Trinidad and Tobago; ## St.Vincent : Saint Vincent and the Grenadines, ### Congo: Democratic Republic of the Congo; #### 
Central A. R.: Central African Republic; * Number of publications per million of population; ** Number of publications per 10 billion US dollars of gross domestic 
product (GDP); *** Number of publications per 1000 US dollars of GDP per capita; **** Number of publications per 100 US dollars of Health expenditure per capita.
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This study has shown a decrease in the number of publications on 
HTLV over a 24 year period (1989-2012). Most scientific production 
has increased over the last few years, although others19,23, like leprosy, 
have experienced reduced trends since the turn of the century34. There 
are different explanations for this decrease, the first of which being 
the decrease in the prevalence of HTLV infection due to the control 
of virus transmission, especially in Japan1. Secondly, the discovery of 
HIV-1 infection in 1983 and the worldwide morbidity and mortality 
impact of AIDS has led to almost all resources being concentrated on 
this disease in the last two decades. In addition, most retrovirologists 
have focused on the HIV field and HTLV infection has been forgotten. 
Thirdly, since the disease associated with HTLV-2, and HAM/TSP or 
ATLL associated with HTLV-1 infection are poorly prevalent and do not 
have an effective therapy3,6, there is not much research interest within the 
scientific community. Finally, there is no effective antiretroviral therapy 
in contrast to other infections like HIV, herpesvirus or hepanavirus, and 
Table 2
Top 20 countries and world regions ranked according to total number of publications by forms of human T-lymphotrophic virus (HTLV) types and diseases 
associated with HTLV (Tropical spastic paraparesis and adult T cell leukemia/lymphoma) in 6,590 HTLV manuscripts with institutional address of the first author.
HTLV-1 HTLV-2 Tropical spastic paraparesis Adult T cell leukemia/lymphoma
Country N. of 
docs.
% Country N. of 
docs.
% Country N. of 
docs.
% Country N. of 
docs.
%
Japan 1,858 31.7 USA 459 43.6 Japan 473 37.7 Japan 417 51.4
USA 1,738 29.7 Brazil 110 10.4 USA 235 18.7 USA 195 24.0
France 499 8.5 France 78 7.4 Brazil 167 13.3 France 53 6.5
Brazil 343 5.9 Japan 65 6.2 France 92 7.3 Brazil 30 3.7
UK 232 4.0 Italy 63 6.0 UK 65 5.2 UK 16 2.0
Italy 162 2.8 Spain 37 3.5 Chile 32 2.5 Germany 14 1.7
Germany 101 1.7 Argentina 30 2.8 Italy 17 1.4 Lebanon 12 1.5
Canada 74 1.3 UK 25 2.4 Canada 17 1.4 Italy 9 1.1
Spain 62 1.1 Belgium 23 2.2 Spain 16 1.3 Canada 8 1.0
Belgium 51 0.9 Canada 13 1.2 Jamaica 15 1.2 China 6 0.7
Israel 44 0.8 Netherlands 13 1.2 Germany 14 1.1 Chile 5 0.6
Chile 43 0.7 Sweden 12 1.1 Peru 12 1.0 Iran 5 0.6
China 43 0.7 Peru 10 0.9 Colombia 11 0.9 Greece 4 0.5
Australia 37 0.6 Germany 9 0.9 Israel 8 0.6 Peru 3 0.4
Peru 37 0.6 Ireland 9 0.9 Belgium 6 0.5 Colombia 3 0.4
Argentina 34 0.6 Mexico 8 0.8 Australia 6 0.5 Argentina 3 0.4
Jamaica 33 0.6 Israel 6 0.6 Sweden 6 0.5 Netherlands 3 0.4
Netherlands 31 0.5 Norway 6 0.6 South Africa 6 0.5 Senegal 3 0.4
Denmark 30 0.5 Cuba 5 0.5 Argentina 4 0.3 Spain 2 0.2
Sweden 29 0.5 Saudi Arabia 5 0.5 China 3 0.2 Jamaica 2 0.2
HTLV-1 HTLV-2 Tropical spastic paraparesis Adult T cell leukemia/lymphoma
World region N. of 
docs.
% World region N. of 
docs.
% World region N. of 
docs.
% World region N. of 
docs.
%
Asia 1,960 33.5 North America 472 44.8 Asia 482 45.8 Asia 426 40.5
North America 1,812 30.9 Europe 295 28.0 North America 252 23.9 North America 203 19.3
Europe 1,299 22.2 Latin America & 
the C.
175 16.6 Latin America & 
the C.
251 23.8 Europe 110 10.4
Latin America & 
the C.
550 9.4 Asia 78 7.4 Europe 230 21.8 Latin America & 
the C.
47 4.5
North Africa 113 1.9 North Africa 18 1.7 Sub-Saharan 
Africa
21 2.0 North Africa 19 1.8
Sub-Saharan 
Africa
80 1.4 Sub-Saharan 
Africa
10 0.9 North Africa 14 1.3 Sub-Saharan 
Africa
7 0.7
Oceania 37 0.6 Oceania 4 0.4 Oceania 6 0.5 Oceania 0 0.0
Total 5,855 100 Total 1,053 100 Total 1,256 100 Total 812 100
N.: number; Docs.: documents; Latin America & C.: Latin America & the Caribbean.
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Table 4
Top 17 authors based on centrality measures and the total number of publications.
Rank Author Betweenness Author Degree Author N of articles
1 Tanaka, Yuetsu 0.000071 Osame, Mitsuhiro 27 Osame, Mitsuhiro 183
2 Bangham, Charles RM 0.000056 Izumo, Shuji 20 Tanaka, Yuetsu 138
3 Kamihira, Shimeru 0.000053 Nakamura, Tatsufumi 18 Gessain, Antoine 121
4 Yamaguchi, Kazunari 0.000050 Gessain, Antoine 17 Izumo, Shuji 101
5 Yamada, Yasuaki 0.000047 Soriano, Vicente 17 Jacobson, Steven 96
6 Okayama, Akihiko 0.000039 Tanaka, Yuetsu 16 Lairmore, Michael D 93
7 Osame, Mitsuhiro 0.000032 Murphy, Edward L 15 Lal, Renu B 77
8 Fujii, Masahiro 0.000029 Yamada, Yasuaki 14 Murphy, Edward L 76
9 Kannagi, Mari 0.000028 Kamihira, Shimeru 13 Yamaguchi, Kazunari 74
10 Izumo, Shuji 0.000020 Bangham, Charles RM 12 Bangham, Charles RM 72
11 Hisada, Michie 0.000019 Nagataki, S 12 Blattner, WA 69
12 Utsunomiya, Atae 0.000017 Usuku, Koichiro 11 Taylor, Graham P 66
13 Yamamoto, Naoki 0.000016 Yamamoto, Naoki 11 Nakamura, Tatsufumi 65
14 Murphy, Edward L 0.000016 Yamaguchi, Kazunari 10 Yamamoto, Naoki 62
15 Sonoda, Shunro 0.000016 Okayama, Akihiko 10 Okayama, Akihiko 61
16 Uozumi, Kimiharu 0.000016 Eguchi, Katsumi 10 Brady, John N 60
17 Hanchard, Barrie 0.000013 Tomonaga, Masao 10 Sonoda, Shunro 60
Table 3
Twenty most-productive authors ranked according to total number of publications by forms of human T-lymphotrophic virus (HTLV) types and diseases associated 
with HTLV (Tropical spastic paraparesis and adult T cell leukemia/lymphoma). 
Total HTLV-1 (n=6,697) HTLV-2 (n=1,259) Tropical spastic paraparesis (n=1,422)
Adult T cell leukemia/lym-
phoma (n=900)
Author N. of docs. Author
N. of 
docs. Author
N. of 
docs. Author
N. of 
docs. Author
N. of 
docs.
Osame, M 217 Osame, M 146 Lal, RB 64 Osame, M 170 Matsuoka, M 48
Gessain, A 158 Tanaka, Y 142 Murphy, EL 58 Izumo, S 91 Yamada, Y 42
Tanaka, Y 150 Gessain, A 141 Soriano, V 48 Jacobson, S 77 Mori, N 39
Jacobson, S 112 Jacobson, S 96 Gessain, A 40 Usuku, K 56 Tomonaga, M 37
Izumo, S 110 Lairmore, MD 95 Kaplan, JE 39 Nakamura, T 51 Tanaka, Y 34
Lairmore, MD 103 Yamaguchi, K 95 Hall, WW 35 Bangham, CRM 45 Utsunomiya, A 27
Yamaguchi, K 99 Bangham, CRM 92 Poiesz, BJ 33 Cartier, L 41 Kamihira, S 26
Bangham, CRM 96 Izumo, S 83 Green, PL 30 Kubota, R 40 Yamaguchi, K 25
Lal, RB 93 Matsuoka, M 80 Rudolph, DL 30 Araújo, AQC 35 Gessain, A 22
Blattner, WA 86 Blattner, WA 75 De Thé, G 28 Gessain, A 33 Kannagi, M 22
Murphy, EL 85 Taylor, GP 74 Khabbaz, RF 28 Saito, M 32 Ohshima, K 22
Soriano,V 84 Franchini, G 70 Vandamme, AM 27 Itoyama, Y 31 Ikeda, S 21
Matsuoka, M 83 Mori, N 69 Bertazzoni, U 25 Nagataki, S 29 Hermine, O 21
Taylor, GP 80 Jeang, K-T 68 Lairmore, MD 24 Kira, JI 29 Masuda, M 21
Nakamura, T 76 Lal, RB 67 Chen, IYS 24 Nakagawa,M 28 Takatsuki, K 20
Franchini, G 71 Murphy, EL 67 Mahieux, R 23 Taylor, GP 27 Watanabe, T 19
Takatsuki, K 70 Soriano, V 67 Casoli, C 23 Ijichi, S 27 Sonoda, S 18
Sonoda, S 70 Watanabe, T 67 Blattner, WA 21 Nagai, M 25 Bazarbachi, A 17
Mahieux, R 69 Takatsuki, K 66 Gutiérrez, M 21 Umehara, F 25 Waldmann, TA 16
Watanabe, T 69 Sonoda, S 66 Rosenblatt, JD 21 Eguchi, K 24 Maeda, Y 16
N.: number; Docs.: documents.
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pharmaceutical financial support is extremely low. Therefore, although 
the availability of new journals in PubMed focusing on retroviruses, like 
Retrovirology24, may provide a positive feedback for HTLV research 
papers, there is less interest in this field than before19,23. 
Although most HTLV manuscripts are written in English (89.1%), 
following the trends for scientific diffusion in the research field23, another 
relevant language was Japanese (5.1%). HTLV is endemic in Japan3-5, 
which might explain the prevalence of this language with respect to 
others. 
Original papers were the most commonly retrieved document type 
(approximately 77.8%), similar to other bibliometric studies on virus 
research23. Although controlled trials offer the best evidence for medical 
intervention efficacy30, in this study they represented only 0.8% of the 
documents, which would explain the resulting absence of effective 
antiretroviral therapy for HTLV infection. 
Japan was the leading country in publication output on HTLV. As 
HTLV is endemic in Japan3-5, this might explain the prevalence of this 
country with respect to others. USA, which was the second country, 
has excelled in virology19,22 as well as other biomedical fields31. France 
was the third country, with more HTLV publications than in any other 
biomedical field31-34, probably due to a higher relevance of virology 
research in this country. 
HTLV is also endemic in South America, especially among several 
native peoples35,36. Brazil was the fourth country, and led scientific 
production on HTLV in Latin America. Moreover, this country has 
increased its overall production during the study period as well as 
its relative contribution. This can be attributed to a greater research 
projection for the future and the large population living there, as well 
as to the number of researchers and the development of the country’s 
scientific system, which has become the main scientific reference for 
South America22,37. Brazil also has a large stake in neglected tropical 
diseases, which are a priority for public health due to their high incidence 
(Chagas diseases or Leishmaniasis)34,38. In several bibliometric studies on 
other neglected diseases34,38, Brazil has been a leading country in South 
America, and is, to be more precise, important as a South American 
network core. Although HTLV is endemic to central Australia among 
indigenous Australians, virology and clinical aspects of HTLV infection 
remain poorly described and there are scanty scientific publications from 
Australia39. 
In HTLV-1 and ATLL, the leading countries were Japan and USA 
followed by France. In HTLV-2 the leading country was USA followed by 
Brazil and France. HTLV-2 research was less important among Japanese 
scientists, which is due to the fact that HTLV-2 infects intravenous 
drug users (IDUs) in USA and Europe, and Amerindian tribes in Latin 
American countries40. 
In HAM/TSP, the leading country was Japan, followed by USA and 
Brazil. The HAM/TSP incidence density among HTLV-1-seropositive 
cases observed in current asymptomatic individuals in Brazil is higher 
than that in studies in other countries41,42. For intance, Brazilian scientists 
had a special relevance in research on HTLV with HAM/TSP27,41. 
Asia and North America were the world’s leading areas in scientific 
production on HTLV. In HTLV-2, the interest of research in European 
countries was greater than in Asian countries such as Japan. Europe, 
which has more IDUs, had more cases for HTLV infection, which 
consequently arouses interest in HTLV-2 research. Moreover, USA and 
Europe have a long tradition of agencies and institutions implementing 
research and health programs and lead in scientific production. North 
Fig. 2 - Main research foci in scientific publications on HTLV. Shapes: ellipse (research focus on HTLV-1-associated myelopathy/Tropical spastic paraparesis); triangle (research focus on 
Adult T-cell leukemia/lymphoma).
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America, Japan and Europe are at the vanguard of scientific excellence 
and development, and should increase their collaboration with scientific 
publications in developing countries, especially publications in the field 
of HTLV from Latin America and the Caribbean. 
The progressive growth in collaboration over the last few decades 
is one of the defining features of the evolution of science43,44. By 
applying SNA to coauthorship in scientific publications, we identified 
the existing research groups in the field and the principal investigators 
active in them. Within the networks, it is possible to distinguish a few 
nodes that stand out from the rest. These nodes, identified through 
centrality measures, represent a limited number of influential authors 
who act as intermediates, favoring cohesion between different areas of 
the network and facilitating a rapid connection (i.e. a minimal number 
of steps) between the researchers and groups that participate in the 
broader network. A few nodes play also an important role as “bridges” 
that connect different foci in the network. If these authors disappear, the 
overall connectivity of the network would diminish, and its effectiveness 
would be undermined45. Although there is no consensus on the exact 
significance of centrality measures, some studies have related these 
measures to the greater quantity or quality of research produced46; 
or they have been used as a predictor of preferential attachment by 
newcomers to the research community47.
We used the PubMed database because it is easily accessible and 
widely used; it uses a controlled vocabulary for indexing and recovering 
documents32,33,35, and the index journal in Medline has a certain 
criteria for quality33. However, the method we used may have several 
limitations, which have been explained in other publications4. For 
example, the database mainly includes journals published in English, 
and journals in other languages are less likely to be found in PubMed. 
However, this database has more non-English journals than the Web 
of Science database48. Another limitation is that in PubMed, only the 
first author’s address appear in the journal articles, so it is not possible 
to estimate the quantity of articles from multinational collaborations. 
This may cause some problems when estimating research productivity 
from developing countries that work in collaboration with scientists 
from a developed country. Even though the bibliometric methodology 
used may present some limitations and the results could, in some way, 
be biased49,50, we believe that this study represents a useful tool for 
scientists and public health policy makers to plan and organize research 
in the field of HTLV. 
CONCLUSIONS
Authors affiliated with institutions in Japan and USA led scientific 
production in HTLV research. Efforts should be made to help low-
income countries with the highest prevalence of HTLV to promote 
scientific research networks (collaborative platforms) with Japan, 
North American and/or European countries in order to increase 
research based on virology, epidemiology, and/or clinical implications 
of HTLV infection. HTLV infection is a life-long infection and is 
currently incurable and untreatable. For this reason, HTLV infection, 
as a neglected disease, would provide more focus on this condition, 
perhaps increasing the number of researchers in this field and promoting 
research collaboration, which could lead to the development of better 
treatment options for patients. 
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